Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
SOUTH SAN FRANCISCOGenentech Inc. has submitted a supplemental Biologics License Application (sBLA) to FDA for bevacizumab (Avastin) in combination with platinum-based chemotherapy for first-line treatment of advanced, non-squamous, non-small-cell lung cancer (NSCLC). The company has requested priority review on the submission. In a phase III trial (E4599) in patients with locally advanced, metastatic, or recurrent NSCLC, Avastin plus paclitaxel and carboplatin improved overall survival by 25%, compared with chemotherapy alone.
Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer
September 18th 2018ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.